Esterase responsive cationic lipid molecules for gene delivery
By designing esterase-responsive cationic lipid molecules, using esterase to catalyze the degradation of positive charge of quaternary ammonium salts, the complete dissociation of gene drugs is solved, and the stability and toxicity of the gene vaccine delivery system in the prior art is improved, and transfection is improved Efficiency and biosafety.
Patent Information
- Application Number
- CN202310593812.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-05-23
AI Technical Summary
In the existing gene vaccine delivery system, there are bottlenecks in the stability and storage and transportation of lipid nanoparticles, and the quaternary ammonium cationic carrier is incompletely dissociated in the cytoplasm, resulting in low transfection efficiency and potential toxicity.
Design an esterase-responsive cationic lipid molecule with hydrolysis and conversion to electroneutral or negatively charged compounds under the action of lactonease, and generate negatively charged carboxylic acid groups through autocatalytic ester bond hydrolysis, reducing the positive charge of quaternary ammonium salts , achieve complete dissociation and efficient transfection of genetic drugs.
It improves the transfection efficiency of gene drugs, reduces the toxicity of the vector, and significantly improves the stability and biosafety of the gene delivery system.
Smart Images

Figure CN119019276A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of nano-biomaterial production, in particular to an esterase-responsive cationic lipid molecule for gene delivery. Background Art
[0002] The working principle of gene vaccines is: after the antigen gene is delivered to the host cell cytoplasm or nucleus, the host cell regards it as an endogenous gene and uses the host cell's transcription and translation mechanisms to produce related antigens and trigger an adaptive immune response (IM Alfagih, B. Aldosari, B. Al Quadeib, et al., Nanoparticles as Adjuvants and Nanodlivery Systems for mRNA-Based Vaccines. Pharmaceutics, 2020. 13 (1)). Compared with traditional vaccines such as attenuated vaccines, inactivated pathogens, and subunit vaccines, it has the advantages of no metabolic toxicity, can induce humoral immunity and cellular immunity at the same time, and has a short development cycle. Among the many delivery systems, non-viral vectors such as liposomes or lipid nanoparticles prepared using lipids or lipid-like materials dominate. Lipid nanoparticles used for gene delivery usually contain four components: amine-containing lipids or lipid-like molecules, phospholipid molecules, cholesterol and lipid-anchored polyethylene glycol (JBMiller and DJSiegwart, Design of synthetic materials for intracellular delivery of RNAs: From siRNA-mediated gene silencing to CRISPR / Cas gene editing. Nano Research, 2018. 11 (10): 5310-5337.). Amine-containing lipids usually contain ionizable amino structures such as tertiary amines, which are protonated when the pH is less than the amino group pKa, and bind negatively charged DNA or RNA through electrostatic interaction. Phospholipid molecules participate in the membrane formation, and cholesterol promotes membrane fusion and improves the stability of nanoparticles; lipid-anchored polyethylene glycol can prolong the half-life of nanoparticles (TMAllen and PRCullis, Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev, 2013. 65 (1): 36-48.). For example, the announcement number CN 110638759A discloses an mRNA preparation for in vitro transfection and in vivo delivery. The lipid molecules used to bind to mRNA in this invention are ionizable lipid molecules and cationic lipid molecules, but the lipid molecules are not degradable in the body and may cause potential toxicity. At the same time, it is found in the application practice of gene vaccines that product stability and storage and transportation are a major bottleneck. Current gene vaccines have extremely high requirements for storage conditions and need to be stored at extremely low temperatures, which is costly and inconvenient to use.The main factor for the instability of the formulation is that the positive charge density of the amine-containing lipids in the lipid nanoparticle delivery system is low, and the electrostatic interaction with the gene binding is weak, which leads to the instability and inactivation of the lipid nanoparticles.
[0003] Previous studies have shown that the use of high-density cationic polymers or cationic liposomes can effectively compress genetic material. Compared with tertiary amine structure carriers, cationic carriers containing quaternary ammonium salt structures can form more stable complexes with genetic material. However, the strong positive charge of quaternary ammonium salt cationic carriers will lead to incomplete dissociation of the complex in the cytoplasm, and the genetic material cannot be released for transfection, reducing the transfection efficiency. Therefore, the high extracellular stability and complete intracellular dissociation of the complex formed by the gene drug and the carrier are a contradiction. Announcement No. CN 106146834 A discloses an esterase-responsive cationic polymer for preparing DNA complexes for gene transfection. After the delivery system is hydrolyzed by enzyme catalysis, the high molecular weight polymer main chain is not degraded, which will show potential toxicity; and the tertiary amine structure still exists on the polymer main chain, which cannot completely dissociate the nucleic acid drug, reducing the transfection efficiency of the nucleic acid drug. Summary of the invention
[0004] The purpose of the present invention is to solve the problem of XX and provide an esterase-responsive cationic lipid molecule for gene delivery. The liposome formed by the cationic lipid molecule has good stability in vitro, and the carrier has low toxicity in vivo, and can be efficiently and completely dissociated from the gene, thereby maximizing protein translation and improving transfection efficiency.
[0005] The technical solution adopted by the present invention to solve its technical problem is: An esterase-responsive cationic lipid molecule for gene delivery, which can be hydrolyzed by intracellular esterase to convert into a neutral or negatively charged compound, which is a X group and n The compound formed by connection, n = 1, 2, 3 or 4, has the following composition structure: The R1 is a C1-C4 alkyl or aromatic group, the R2 is a C1-C4 alkyl or aromatic group, and R3 is a C5-C30 aliphatic chain or a condensed ring hydrophobic group; X is one of an amino group, a substituted aminoethyl group, a hydroxyl group, an ether bond, a thioether group, and a piperazine group, Or X is One of; The R4 is one of CH2CH2, CH2CH2CH2, and CH2CH2CH2CH2.
[0006] The condensed ring hydrophobic groups include cholesterol and bile acid.
[0007] The anion is chloride or bromide.
[0008] The esterase responds to the cationic lipid molecule and specifically selects one of the compounds of the following structures: (1) (2) (3) (4) (5) (6) (7) (8) (9)
[0009] The esterase of the present invention responds to the cationic lipid molecules that can be hydrolyzed by intracellular esterase to remove the positive charge of the quaternary ammonium salt, and then generates a negatively charged carboxylic acid group through self-catalytic ester bond hydrolysis. Taking the above compound (3) as an example, the charge reversal process is shown in the following formula:
[0010] Esterase-responsive cationic lipid molecules were prepared by a two-step synthetic method: Step 1: First, a compound containing primary amine or secondary amine and aminoethyl acrylate are stirred in an alcohol solvent at a molar ratio of 1:1-4, the stirring reaction temperature is controlled at 20-80°C, and the stirring reaction time is 12-72h to generate an intermediate product containing a tertiary amine structure; Step 2: The intermediate product containing a tertiary amine structure is purified by precipitation or column chromatography, and then the intermediate product containing a tertiary amine structure is dissolved in an organic solvent, and then one of 4-bromomethylphenol alkyl ester, 4-bromomethylphenol olefin ester, 4-chloromethylphenol alkyl ester, and 4-chloromethylphenol olefin ester is added, and the reaction is stirred for 12-72 hours, and the reaction temperature is controlled at 20-80°C. After the reaction is completed, the organic solvent is removed, and the esterase-responsive cationic lipid molecule is obtained after purification by precipitation.
[0011] Compounds containing primary or secondary amines include: ethylenediamine, N,N-dimethylethylenediamine, N,N'-dimethylethylenediamine, 1,4-bis(3-propyl)piperazine, N,N-bis(3-propyl)methylamine, N1,N1'-(propane-1,3-diyl)bis(N1methylethyl-1,2-diamine), N1-(3-aminopropyl)-N1,N3,N3-trimethylpropyl-1,3-diamine.
[0012] The alcohol solvent is methanol, ethanol or isopropanol; the organic solvent is one of methanol, N,N-dimethylformamide and dimethyl sulfoxide.
[0013] Application of esterase-responsive cationic lipid molecules as nucleic acid drug delivery vehicles.
[0014] The esterase-responsive cationic lipid molecules of the present invention carry a large amount of positive charges of quaternary ammonium salts, and can form stable nanocomposites with negatively charged nucleic acid drugs through electrostatic self-assembly. After entering the cells, the quaternary ammonium salts react under the action of esterases, and the quaternary ammonium salts are converted into tertiary amines, which can then be hydrolyzed by self-catalytic ester bonds to generate electrically neutral or negatively charged compounds, thereby mutually repelling the nucleic acid drugs and rapidly dissociating, completely releasing the nucleic acid drugs, and performing efficient transfection.
[0015] The present invention also discloses the use of the esterase-responsive cationic lipid molecule as a gene delivery vector and its application in gene delivery. The present invention prepares a highly efficient, low-toxic non-viral gene delivery vector, and the nanocomplex formed by the vector and the nucleic acid drug has a high transfection efficiency.
[0016] A gene delivery system comprises a lipid nanoparticle carrier and a nucleic acid drug loaded on the carrier. The lipid nanoparticle carrier is formed by esterase-responsive cationic lipid molecules, auxiliary lipids and PEG lipid molecules. The molar ratio of esterase-responsive cationic lipid molecules: auxiliary lipids: PEG lipid molecules is 40-80:10-40:0.5-2.
[0017] The nucleic acid drug is one of DNA, siRNA, shRNA, micro RNA, and mRNA.
[0018] The beneficial effects of the present invention are as follows: in the present invention, the quaternary ammonium structure has a high cationic charge density, can be tightly bound to DNA or RNA through electrostatic action, and improve the stability of the nanoparticles encapsulating the gene; and can be compounded at a lower N / P ratio, reducing the amount of lipid molecules and thus reducing potential toxicity; and under the catalysis of intracellular esterase, the cationic lipid molecules decompose to form non-toxic electrically neutral or negatively charged molecular fragments, thereby completely releasing the gene for transfection. While solving the problems of stability and biosafety of the gene drug system, the delivery system significantly improves the gene transfection effect and is used for the treatment of related diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 The charge reversal potential of the cationic lipid molecule of Example 1-5; Figure 2 This is the data diagram of orthogonal experiment ratio screening transfection in Example 4; Figure 3 The particle size diagram of the nanoparticles formed by the cationic lipid molecules of Examples 1-5; Figure 4 The potential diagram of nanoparticles formed by cationic lipid molecules of Examples 1-5; Figure 5 Gene transfection of nanoparticles formed by cationic lipid molecules of Example 1-5 to express luciferase protein; Figure 6 The cytotoxicity data of the nanoparticles formed by the cationic lipid molecules of Examples 1-5; Figure 7 These are in vivo imaging images of nanoparticles formed by cationic lipid molecules in Example 4 injected intravenously at different times in vivo; Figure 8 Comparative data of bioluminescence intensity of nanoparticles formed by cationic lipid molecules in Example 4 at different times of intravenous injection in vivo; Fig. 9 Flow cytometry comparison data of DC cell maturation stimulation in Examples 3 and 4; Fig.10 This is the growth inhibition curve of B16-OVA subcutaneous tumor by lipid nanoparticles in Example 4. DETAILED DESCRIPTION
[0020] The technical solution of the present invention is further described in detail below through specific embodiments.
[0021] In the present invention, unless otherwise specified, the raw materials and equipment used can be purchased from the market or are commonly used in the art. The methods in the following embodiments, unless otherwise specified, are all conventional methods in the art.
[0022] definition: Representative examples of helper lipids include, but are not limited to, phosphatidylcholine, distearoylphosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, palmitoyloleoylphosphatidylcholine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylcholine, distearoylphosphatidylcholine, dioleoylcholine, trimethyl-2,3-dioleyloxypropylammonium bromide, trimethyl-2,3-dioleyloxypropylammonium chloride, 3β-[N-(N',N'-dimethylaminoethyl)carbamoyl]cholesterol, dioleoylphosphatidylethanolamine, dimyristoylphosphatidylcholine, hydrogenated soybean phosphatidylcholine, dipalmitoylsphingomyelin.
[0023] Representative examples of PEG lipids include, but are not limited to, dimyristoylglycerol-polyethylene glycol 2000, distearoylphosphatidylethanolamine-polyethylene glycol 2000, DMA-PEG2000, PEG2000-Ceramide-C14.
[0024] Depending on the intended use of the lipid particle, the ratio of the components can be varied and the delivery efficiency of the lipid particle tested using assays known in the art.
[0025] Example 1 Synthesis of compound (1): 1g N,N,N'-trimethylethylenediamine and 1.4g dimethylaminoethyl acrylate were stirred in 10mL methanol at 40°C for 24h. After the reaction, methanol was removed and column chromatography was performed for purification (mobile phase: dichloromethane / methanol = 9 / 1). Then 1g of the purified compound was dissolved in 5mL N,N-dimethylformamide (DMF), 0.63g 4-bromomethylphenol hexyl ester was added, and stirred at 20°C for 24h. DMF was removed, precipitated with ether, and the precipitate was collected to obtain the cationic lipid molecule EMM-PC6 with a yield of 90%. The structure is as follows:
[0026] Example 2 Synthesis of compound (2): 1g N,N-dimethylethylenediamine and 3.25g dimethylaminoethyl acrylate were stirred in 10mL methanol at 60°C for 48h. After the reaction, methanol was removed and purified by column chromatography (mobile phase: dichloromethane / methanol = 95 / 5). Then 1g of the purified compound was dissolved in 5mL DMF, 1.73g 4-chloromethylphenol dodecyl ester was added, and stirred at 40°C for 24h. DMF was removed, precipitated with ether, and the precipitate was collected to obtain the cationic lipid molecule EMTM-PC12 with a yield of 83%. The structure is as follows:
[0027] Example 3 Synthesis of compound (3): 1g N,N-dimethylethylenediamine and 3.9g diethylaminoethyl acrylate were stirred in 10mL isopropanol at 40°C for 12h. After the reaction, the isopropanol was removed and column chromatography was performed for purification (mobile phase: dichloromethane / methanol / triethylamine = 90 / 9 / 1). Then 1g of the purified compound was dissolved in 5mL dimethyl sulfoxide, 1.74g 4-chloromethylphenol dodecyl ester was added, and stirred at 80°C for 12h. The dimethyl sulfoxide was removed, precipitated with n-hexane, and the precipitate was collected to obtain the cationic lipid molecule APB-AC12 with a yield of 71%. The structure is as follows:
[0028] Example 4 Synthesis of compound (4): 0.36g N,N-bis(3-aminopropyl)methylamine and 2.27g dibutylaminoethyl acrylate were stirred in 10mL isopropanol at 50°C for 72h. After the reaction, methanol was removed and column chromatography was performed for purification (mobile phase: dichloromethane / methanol = 20 / 1). Then 0.2g of the purified compound was dissolved in 5mL DMF. Then 0.45g 4-bromomethylphenol oil ester was added and stirred at 80°C for 12h. DMF was removed, precipitated with n-hexane, and the precipitate was collected to obtain the cationic lipid molecule AMB-P℃18 with a yield of 86%. The structure is as follows:
[0029] Example 5 Synthesis of compound (5): 0.5g N-methylethylenediamine and 3.47g diethylaminoethyl acrylate were stirred in 10mL ethanol at 20°C for 24h. After the reaction, methanol was removed and column chromatography was performed for purification (mobile phase: dichloromethane / methanol = 20 / 1). Then 0.2g of the purified compound was dissolved in 5mL DMSO, 0.46g 4-bromomethylphenol octadecyl ester was added, and stirred at 70°C for 48h. DMSO was removed, precipitated with n-hexane, and the precipitate was collected to obtain the cationic lipid molecule DMB-AC18 with a yield of 64%. The structure is as follows:
[0030] Application Example 1 Dissolve the pig liver esterase in 100mM Tris-HCl buffer solution containing 100mM NaCl to prepare a mother solution with an enzyme concentration of 120units / mL. Dissolve the cationic lipid compound of Example 1-5 in DMSO to prepare a solution with a concentration of 30mg / mL, take 0.2mL of the solution and add it to 1.0mL of esterase solution. Place the solution in a 37°C constant temperature incubator. Take 100μL of samples at different time points and add them to 1mL of acetonitrile to terminate the enzymatic reaction. Centrifuge the solution at 6000rpm for 5min, take the supernatant, and measure the potential.
[0031] according to Figure 1 As shown, under the action of esterase, the potential of the cationic lipid molecules in Examples 1-5 decreased to neutral or negative charge over time, indicating that they can undergo charge reversal under physiological conditions, which is beneficial to the dissociation of genes and reduces the toxicity of the vector.
[0032] Application Example 2 Examples 1-5 were prepared into nanoparticles: cationic lipids, auxiliary lipids and PEG lipids were dissolved in ethanol solution according to the formula to obtain an organic phase with a total concentration of 1 mg / mL, and mRNA was dissolved in citric acid-sodium citrate buffer (pH=3, concentration of 10 mM) to obtain an aqueous phase with a concentration of 1 mg / mL. The two were mixed in equal volumes, vortexed and dialyzed in pH=5, 20 mM MES buffer, and a lipid nanoparticle solution was obtained after 1 hour.
[0033] Exploration of the optimal formulation ratio: Enhanced green fluorescent protein mRNA (EGFP) was used as a reporter gene to react to in vitro cell transfection efficiency. The cationic lipid molecules and mRNA molecules in Example 4 were mixed at different N / P ratios for Hela cell transfection experiments to screen out the optimal N / P ratio. A three-factor four-level orthogonal experiment was set up based on the N / P ratio to screen out the optimal ratio for Hela cell transfection experiments. Among them, the three factors include: cationic lipid molecules, auxiliary lipids (taking DOPE as an example) and PEG lipids (taking DMG-PEG2000 as an example), and the units are in moles.
[0034] Cationic lipid molecules DOPE DMG-PEG 1 50 10 0.5 2 50 20 1 3 50 30 1.5 4 50 40 2 5 60 10 1 6 60 20 0.5 7 60 30 2 8 60 40 1.5 9 70 10 1.5 10 70 20 2 11 70 30 0.5 12 70 40 1 13 80 10 2 14 80 20 1.5 15 80 30 1 16 80 40 0.5 The results are analyzed as Figure 2 As shown, according to the mean main effect analysis, the optimal ratio of the orthogonal experiment is cationic lipid molecules: DOPE: DMG-PEG2000 molar ratio = 50:20:0.5, and the proportions of nanoparticle components in other application examples all adopt this ratio.
[0035] Application Example 3 Cationic lipid molecules in Examples 1-5 were used to prepare lipid nanoparticles according to a molar ratio of cationic lipid molecules: DOPE: DMG-PEG2000 = 50:20:0.5, and the particle size potential was measured: the prepared lipid nanoparticle solution was taken and its size and Zeta potential were measured using a dynamic light scattering instrument at 25°C. The results were calculated using DTS software. Each group was repeated 3 times and the average value was taken. Figure 3 and Figure 4 The particle size of the nanoparticles is between 90-250nm, the PDI is below 0.25, and the potential is between -5 and 15mV.
[0036] Application Example 4 Luciferase mRNA cell transfection experiment of lipid nanoparticles: Hela cells were cultured in 96-well plates with a cell density of 20,000 cells / well, each well contained 0.4 mL of culture medium, and the cells were placed in a 37°C constant temperature incubator with 5% CO2 concentration and 95% humidity for 24 hours. After that, the culture medium in each well was replaced with 0.4 mL of culture medium, and the prepared lipid nanoparticle solution (containing 0.1 μg of luciferase mRNA) was added respectively, and the culture was continued for 24 hours. Dlin-MC3-DMA ionizable lipid molecules and their commercially available liposomes were used as control groups. The culture medium was discarded, 100 μL of cell lysis solution was added to each well, and the luciferase substrate was added after the cells were fully lysed, and the chemiluminescence intensity was measured using a chemiluminescence detector. The protein concentration was measured using a Bradford protein detection kit. The chemiluminescence intensity was normalized using the protein concentration, and the unit was the luminescence intensity per milligram of protein (RLU / mg protein). Each set of data was the average of three wells in the same group of samples.
[0037] Figure 5 The transfection of the nanoparticles composed of cationic lipids in Examples 1-5 in Hela cells. The nanoparticles composed of Examples 2, 4 and 5 expressed higher luciferase protein expression in Hela cells than the commercial Dlin-MC3-DMA liposomes. And compared with the A1 polymer in Publication No. CN 106146834 A, under the condition of N / P of 20, its mRNA protein translation effect was weaker than that of the nanoparticles composed of cationic lipids in Examples 1-5.
[0038] Application Example 5 Toxicity experiment of cationic lipid molecules and corresponding lipid nanoparticles: 3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide (MTT) was used to detect the in vitro cytotoxicity of cationic lipid molecules and corresponding lipid nanoparticles in Hela cells. The cells were cultured in 96-well plates with a cell density of 5000 cells / well, and 180 μL of culture medium was added to each well. The cells were cultured in a 37°C constant temperature incubator with 5% CO2 and 95% humidity for 24 hours. After 24 hours, 20 μL of lipid molecule culture medium solution or lipid nanoparticle culture medium solution of different concentrations (the concentration gradient setting is determined according to the molar amount of cationic lipid molecules required for a certain N / P ratio) was added to each well, and 20 μL of culture medium solution was added to the blank group, and the cells were cultured for 48 hours. The complex formed by Lipofectamine 2000 and mRNA was used as the control group. After 48 hours of culture, add 20 μL of MTT solution (5 mg / mL) and incubate at 37°C for 4 hours, centrifuge at 2500 rpm for 5 minutes, discard the MTT culture medium in each well and add 100 μL of DMSO, shake to dissolve all the crystals in each well. Finally, use an ELISA reader to test the absorbance of the sample at 562 and 620 nm. The cell survival rate (percentage) is expressed as the absorbance value of the experimental group divided by the absorbance value of the blank group. Each set of data is the average of three wells of the same group of samples.
[0039] Figure 6 The cytotoxicity data of the nanoparticles prepared in Examples 1-5 show that within the normal concentration range of the nanoparticles, the cytotoxicity is low and is less toxic than the complex formed by Lipofectamine 2000.
[0040] Application Example 6 In vivo transfection organ distribution and delivery efficiency: Referring to the preparation process of Application Example 2, the cationic lipids in Example 4 were selected according to the optimal ratio to prepare lipid nanoparticles, and 5 μg of mRNA of the reporter gene luciferase was delivered to mice via tail vein injection. The luciferase substrate was injected into the treated mice after 1h, 3h, 6h, 12h, and 24h, respectively. After 10min, the mice were anesthetized and dissected, and the expression site and intensity changes of luciferase in the mice were observed by the fluorescent in vivo imaging system.
[0041] pass Figure 7 The bioluminescence intensity of luciferase was observed at different time points, indicating that the lipid nanoparticles were highly expressed in the spleen and had a spleen-targeted enrichment effect. Figure 8 The quantitative bioluminescence intensity showed that the luminescence intensity reached a peak 6 hours after intravenous injection of lipid nanoparticles, indicating that this series of lipid nanoparticles can be used to treat spleen-related diseases and immune diseases.
[0042] Application Example 7 Mouse bone marrow mesenchymal stem cells were extracted to induce BMDC cells. The cells were collected on the sixth day and 5×10 5 The ratio of cells was added to a 24-well plate. After 24 hours, different LNPs formulations in Examples 3 and 4 (containing 0.5 μg OVA mRNA) were used and incubated in complete medium for 24 hours. LPS was used as a positive control group. After co-incubation, BMDCs were collected, rinsed with FACS buffer, incubated with Fc receptor blockers at room temperature, and then stained on ice with fluorophore-labeled anti-CD11c, CD80, and CD86 antibodies. Flow cytometry was used to quantitatively analyze the labeled cells.
[0043] pass Fig. 9 The data show that the lipid nanoparticles formed by the cationic lipid molecules of Examples 3 and 4 according to the optimal ratio have a higher ability to stimulate BMDC maturation than the positive control group, indicating that the lipid nanoparticles can effectively transfect BMDC cells and exert immune function.
[0044] Application Example 13 Lipid nanoparticles were formed by using cationic lipid molecules in Example 4 according to the optimal ratio, and loaded with 5 μg of OVA-mRNA. 300,000 B16-OVA cells were injected subcutaneously into C57bl / 6 mice, and the lipid nanoparticles were injected on the fourth and ninth days respectively. An equal volume of PBS was injected as a negative control. The MC3 liposome group and the OVA protein group of the disclosed formula were used as control groups. Fig.10 The data show that the lipid nanoparticle group can effectively inhibit tumor growth. On the 22nd day, the tumor was still small in size, and no mice died. On the 16th and 20th days, the tumor volume of the OVA protein group and the MC3 liposome group was greater than 2000 cm. 3 This indicates that the tumor suppression effect is poor.
[0045] The above-described embodiment is only a preferred solution of the present invention and does not limit the present invention in any form. There are other variations and modifications without exceeding the technical solution described in the claims.
Claims
1. An esterase-responsive cationic lipid molecule for gene delivery, characterized in that It can be hydrolyzed by intracellular esterase to form neutral or negatively charged compounds, which are X groups and n The compound formed by connection, n = 1, 2, 3 or 4, has the following composition structure: The R1 is a C1-C4 alkyl or aromatic group, the R2 is a C1-C4 alkyl or aromatic group, and R3 is a C5-C30 aliphatic chain or a condensed ring hydrophobic group; X is one of an amino group, a substituted aminoethyl group, a hydroxyl group, an ether bond, a thioether group, and a piperazine group, Or X is One of; The R4 is one of CH2CH2, CH2CH2CH2, and CH2CH2CH2CH2.
2. The esterase-responsive cationic lipid molecule for gene delivery according to claim 1, characterized in that: The condensed ring hydrophobic groups include cholesterol and bile acid.
3. The esterase-responsive cationic lipid molecule for gene delivery according to claim 1, characterized in that: The anion is chloride or bromide.
4. The esterase-responsive cationic lipid molecule for gene delivery according to claim 1, characterized in that The esterase specifically selects one of the following structures in response to the cationic lipid molecule: (1) (2) (3) (4) (5) (6) (7) (8) (9) 。 5. The esterase-responsive cationic lipid molecule for gene delivery according to claim 1, characterized in that Prepared by a two-step synthetic method: Step 1: First, a compound containing primary amine or secondary amine and aminoethyl acrylate are stirred in an alcohol solvent at a molar ratio of 1:1-4, the stirring reaction temperature is controlled at 20-80°C, and the stirring reaction time is 12-72h to generate an intermediate product containing a tertiary amine structure; Step 2: The intermediate product containing a tertiary amine structure is purified by precipitation or column chromatography, and then the intermediate product containing a tertiary amine structure is dissolved in an organic solvent, and then one of 4-bromomethylphenol alkyl ester, 4-bromomethylphenol olefin ester, 4-chloromethylphenol alkyl ester, and 4-chloromethylphenol olefin ester is added, and the reaction is stirred for 12-72 hours, and the reaction temperature is controlled at 20-80°C. After the reaction is completed, the organic solvent is removed, and the esterase-responsive cationic lipid molecule is obtained after purification by precipitation.
6. The esterase-responsive cationic lipid molecule for gene delivery according to claim 1, characterized in that Compounds containing primary or secondary amines include: ethylenediamine, N,N-dimethylethylenediamine, N,N'-dimethylethylenediamine, 1,4-bis(3-propyl)piperazine, N,N-bis(3-propyl)methylamine, N1,N1'-(propane-1,3-diyl)bis(N1methylethyl-1,2-diamine), N1-(3-aminopropyl)-N1,N3,N3-trimethylpropyl-1,3-diamine.
7. The esterase-responsive cationic lipid molecule for gene delivery according to claim 1, characterized in that The alcohol solvent is methanol, ethanol or isopropanol; the organic solvent is one of methanol, N,N-dimethylformamide and dimethyl sulfoxide.
8. Use of the esterase-responsive cationic lipid molecule as claimed in claim 1 as a nucleic acid drug delivery carrier.
9. A gene delivery system, characterized in that The invention comprises a lipid nanoparticle carrier and a nucleic acid drug loaded on the carrier. The lipid nanoparticle carrier is formed by the esterase-responsive cationic lipid molecule, auxiliary lipid and PEG lipid molecule according to claim 1. The molar ratio of the esterase-responsive cationic lipid molecule: auxiliary lipid: PEG lipid molecule is 40-80:10-40:0.5-2.
10. The gene delivery system according to claim 9, characterized in that The nucleic acid drug is one of DNA, siRNA, shRNA, micro RNA, and mRNA.
Citation Information
Patent Citations
Cationic polymer with esterase response function
CN106146834A
Preparation used for transfection in vitro and delivery in vivo of mRNA
CN110638759A
Bivalent ionizable lipid compound, composition and application thereof
CN114213346A
Application of ionizable cationic lipid analogue material as nucleic acid drug delivery carrier or transfection reagent
CN114904003A
